Taken together, this study extends our previous finding that genetic variation in COMT differentially influences IBS symptom improvement in response to placebo treatment (5), in particular DBP, and suggests that the COMT rs4680 genetic variant may be useful in predicting, managing, and targeting placebo response in IBS trials and drug development. Here, COMT is linked to irritable bowel syndrome.